Form 4: LOUMEAU ERIC J reports multiple insider transactions in ANAB

Rhea-AI Filing Summary

LOUMEAU ERIC J reported multiple insider transaction types in a Form 4 filing for ANAB. The filing lists transactions totaling 30,000 shares at a weighted average price of $41.85 per share. Following the reported transactions, holdings were 35,000 shares.

Insights

Equity compensation analyst

Preplanned option exercise and sale by AnaptysBio’s CLO looks routine.

Eric J. Loumeau, Chief Legal Officer of AnaptysBio, Inc., exercised employee stock options for 10,000 shares at an exercise price of $29.70 on February 11, 2026. This is classified as a derivative conversion/exercise transaction.

On the same date, he sold 10,000 common shares at $54.00 per share in an open‑market transaction. A footnote states these trades were executed under a Rule 10b5‑1 trading plan adopted on April 11, 2025, indicating they were pre‑scheduled rather than discretionary.

Following these moves, he directly owned 12,835 common shares and retained options on 35,000 shares reported in the table, plus additional options to purchase up to 436,010 shares that vest over time. The filing does not quantify his holdings relative to total shares outstanding, so the broader ownership impact is unclear.

Insider Trade Summary

Net Seller: 10,000 shares ($540,000)

Net Sell 3 txns

Insider LOUMEAU ERIC J

Role CHIEF LEGAL OFFICER

Sold 10,000 shs ($540K)

Type	Security	Shares	Price	Value
Exercise	Employee Stock Option (right to buy)	10,000	$0.00	--
Exercise	Common Stock	10,000	$29.70	$297K
Sale	Common Stock	10,000	$54.00	$540K

Holdings After Transaction: Employee Stock Option (right to buy) — 35,000 shares (Direct); Common Stock — 22,835 shares (Direct)

Footnotes (1)

1. The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person dated April 11, 2025. The stock option is fully vested. In addition to the options to purchase a total of 35,000 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 436,010 shares of common stock, which options vest according to their terms.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LOUMEAU ERIC J

(Last) (First) (Middle)

C/O ANAPTYSBIO, INC.

10770 WATERIDGE CIRCLE, SUITE 210

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ANAPTYSBIO, INC [ ANAB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF LEGAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
02/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/11/2026		M		10,000	A	$29.7	22,835	D
Common Stock	02/11/2026		S(1)		10,000	D	$54	12,835	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$29.7	02/11/2026		M			10,000	(2)	02/09/2031	Common Stock	10,000	$0	35,000(3)	D

Explanation of Responses:

1. The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person dated April 11, 2025.

2. The stock option is fully vested.

3. In addition to the options to purchase a total of 35,000 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 436,010 shares of common stock, which options vest according to their terms.

	/s/ Eric Loumeau	02/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did AnaptysBio (ANAB) report for Eric Loumeau?

AnaptysBio’s Chief Legal Officer, Eric J. Loumeau, exercised options for 10,000 shares at $29.70 and sold 10,000 common shares at $54.00 on February 11, 2026, leaving him with 12,835 directly owned shares afterward.

Was the AnaptysBio (ANAB) insider sale by Eric Loumeau preplanned?

Yes. The Form 4 states the transactions occurred under a Rule 10b5-1 trading plan adopted by Eric Loumeau on April 11, 2025, indicating the exercise and sale were pre-scheduled rather than opportunistic discretionary trades in the open market.

How many AnaptysBio (ANAB) shares does Eric Loumeau own after the Form 4?

After the reported February 11, 2026 transactions, Eric Loumeau directly owns 12,835 shares of AnaptysBio common stock. He also retains options that allow him to purchase additional shares, including 35,000 options reported plus further option grants described in the footnotes.

What stock options did Eric Loumeau exercise in the AnaptysBio (ANAB) Form 4?

He exercised an employee stock option covering 10,000 AnaptysBio common shares at an exercise price of $29.70 per share. The filing notes the option is fully vested, and the underlying shares are reported as common stock in the non-derivative section.

How many AnaptysBio (ANAB) options does Eric Loumeau still hold?

The filing shows options to purchase 35,000 shares in Table II, plus a footnote stating he also holds additional options to buy up to an aggregate of 436,010 AnaptysBio common shares, which vest according to their respective terms over time.

What is the significance of the 10b5-1 plan in the AnaptysBio (ANAB) Form 4?

The 10b5-1 plan means Eric Loumeau’s trades were scheduled in advance under a formal trading arrangement. This structure is designed to separate personal trading decisions from nonpublic information, offering a framework to reduce concerns about timing-based insider trading.